A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

This study tests a new immunotherapy drug called pumitamig (BNT327) in patients with glioblastoma — the most aggressive form of brain cancer — that has come back after initial treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of grade IV glioblastoma (IDH-wildtype) that has recurred - You have received standard treatment (radiation and temozolomide) previously - Your tumor is above the brain stem (supratentorial) - You are in good enough health to participate **You may NOT be eligible if...** - Your glioblastoma is in its first occurrence (not recurrent) - You have active autoimmune conditions requiring treatment - You have previously received immunotherapy for brain cancer - You have significant steroid requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.